Publications

Haws LC, Thompson C, Perry C, White M, Fitzgerald L, Borghoff S, Wikoff D. Development of non-cancer based toxicity factors and daily dose estimates for TBBPA. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Johnson GE, Soeteman-Hernandez, Gollapudi BB, Bodger OG, Dearfield KL, RH Heflich,…, Thompson CM, Abraham L, et al. 2014. Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. Environ Molec Mutagen 55(8):609-623; doi: 10.1002/em.21870/em.21870. PMID: 24801602.

Kirman CR, Proctor D, Suh M, Thompson CM, Harris MA, Haws LC, Hays SM. Variation analysis of PBPK model parameters for describing the delivery of Cr(VI) to the small intestines of humans. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays S, Hixon JG, Harris MA. 2014. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol 34(5):525-536. doi: 10.1002/jat.2907. PMID: 23943231.

Hixon JG, Thompson C, Bichteler A, Abraham L. Smoothing regression splines as the basis for dose-response modeling. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Thompson CM, Proctor DM, Suh M, Wolf JC, Haws LC, Seiter JM, Chappell MA, Harris MA. X-ray fluorescence microspectroscopic analysis of duodenal mucosae following Cr(VI) exposure in drinking water. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Suh M, Thompson C, Kirman C, Carakostas M, Haws LC, Harris M, Proctor D. 2014. High concentrations of hexavalent chromium in drinking water alter iron homeostasis in F344 rats and B6C3F1 mice. Food Chem Toxicol 65(Mar):381-388; doi: 10.1016/j.fct.2014.01.009. PMID: 24418189.

Wikoff D, Thompson C, Perry C, White M, Fitzgerald L, Borghoff S, Haws LC. Development of an oral cancer slope factor and lifetime average daily dose estimates for TBBPA. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Rowlands JC, Budinsky R, Gollapudi B, Black MB, Wolfinger RD, Cukovic D, Bombkowski A, Thompson CM, Urban JD, Thomas RS. 2013. A genomics-based analysis of relative potencies of dioxin-like compounds in primary rat hepatocytes. Toxicol Sci 136(2):595-604; doi: 10.1093/toxsci/kft203. PMID: 24046277.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY. 2013. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol 271(3):299–308; doi: 10.1016/j.taap.2011.01.017. PMID: 21295051.

Urban JD, Thompson CM, Deskin R, Waite M, Haws LC. 2013. Development of an oral cancer slope factor for acrylamide based on tumors relevant to humans. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, et al. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003. PMID: 23603453.

O’Brien T, Ding H, Suh M, Thompson C, Parsons BL, Harris MA,…, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat Res 754(1-2):15-21. doi: 10.1016/j.mrgentox.2013.03.008. PMID: 23583686.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406; doi: 10.1002/jat.2799.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596. PMID: 23445218.

Suh M, Thompson CM, Hixon JG, Harris MA, Kirman CR, Hays S, Haws LC, Proctor DM. Potential involvement of oxidative stress and iron disturbance in the development of oral cavity tumors in rats exposed to hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Thompson CM, Kirman CR, Proctor DM, Suh M,Hays SM, Haws LC, Harris MA. A chronic oral reference dose for hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64; doi: 10.1016/j.cbi.2012.08.016. PMID: 22981460.